CAS: 11034-40-5

Spiramycin hexanedioate is a macrolide antibiotic, which is derived from the bacterium *Streptomyces ambofaciens*. Its mode of action involves binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. This interaction results in the interruption of bacterial growth and reproduction, particularly effective against Gram-positive organisms. Spiramycin hexanedioate is used primarily in the treatment of various bacterial infections, including those affecting the respiratory tract, skin, and soft tissues. It has applications in both human and veterinary medicine, where its efficacy extends to the management of toxoplasmosis in pregnant women due to its ability to reduce the risk of fetal transmission. Researchers have also explored its potential in protozoan parasitic infections. Its pharmacokinetic profile, characterized by high tissue penetration, supports its effectiveness in these therapeutic roles. Understanding the mechanism and scope of spiramycin hexanedioate is crucial for its application in clinical microbiology and pharmacology, ensuring optimal outcomes in infection control.